Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Net Cash Flow (2016 - 2025)

Dexcom (DXCM) has disclosed Net Cash Flow for 16 consecutive years, with -$921.6 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 23530.77% to -$921.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $290.3 million through Dec 2025, up 515.04% year-over-year, with the annual reading at $290.3 million for FY2025, 515.04% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$921.6 million at Dexcom, down from $677.7 million in the prior quarter.
  • The five-year high for Net Cash Flow was $677.7 million in Q3 2025, with the low at -$921.6 million in Q4 2025.
  • Average Net Cash Flow over 5 years is $4.6 million, with a median of -$12.0 million recorded in 2023.
  • The sharpest move saw Net Cash Flow surged 2331.78% in 2023, then plummeted 23530.77% in 2025.
  • Over 5 years, Net Cash Flow stood at -$391.1 million in 2021, then soared by 83.99% to -$62.6 million in 2022, then crashed by 33.23% to -$83.4 million in 2023, then surged by 95.32% to -$3.9 million in 2024, then tumbled by 23530.77% to -$921.6 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$921.6 million, $677.7 million, and $237.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.